Taylor Hudson

Gene Carpenter 🔨🧬🪚🧫

[Taylor Hudson @Trae_1992]

Words can’t express what it meant to work on such a historic case in medicine. It was truly a call to action across institutions to save a life. I think I speak for everyone involved when I say our greatest hope is that medical opportunity becomes accessible to all who need it.

[Robert Sanders @bobthesciguy]

A CRISPR therapy produced in record time benefits an infant with an often deadly hereditary disease, with help from @UCBerkeley https://t.co/JB3iWOwCLx @ChildrensPhila

[Genetic Engineering & Biotechnology News @GENbio]

“It Was Not a Cure”: Musunuru Cautions ASGCT on Baby KJ Promise

@kiranmusunuru, a 2026 ASGCT Catalyst Award winner, reflected on Baby KJ’s legacy. He outlined the FDA conversations required to streamline future #raredisease trials

#ASGCT26 #geneediting
https://t.co/tzrKtSTO56

[Taylor Hudson @Trae_1992]

@DrGauravNarula @IndiACGT @CTCTC_tmc @purwarrahul2 @ActImmuno @ACTREC_TMC @TataMemorial @DBTIndia @KhushaliPandit @AlbeenaDr @AafreenAnsari44 @NaitikaBhavsar @pho_india So good to see a University from India! I hope to see more in years to come!

[Taylor Hudson @Trae_1992]

@fredhutch @HPKiem Loved your talk! You really explained things clearly. It was easy to follow

[Taylor Hudson @Trae_1992]

It was incredibly energizing to finally meet collaborators, mentors and longtime role models in person after years of reading their papers. I appreciate all those who took the time to visit our poster session to discuss off-targets and personalized medicine. #asgct26

[Arc Institute @arcinstitute]

First released one year ago, Evo 2 predicts variant effects & generates functional DNA across all domains of life, from bacteria to humans, from a single set of weights, with no fine-tuning required.

[Taylor Hudson @Trae_1992]

@lucapinello @NatureComms Is it possible some of it was due to template hopping?

[Luca Pinello @lucapinello]

Now published in @NatureComms! See my thread from the preprint for the full breakdown. Stay tuned for more work in this direction! 📄 https://t.co/o5JoWzably

[Taylor Hudson @Trae_1992]

@lucapinello @NatureComms Holy cow!! -- "20.3%-22.9% self-editing frequency in ABE8e-SpRY presort samples" .. I wonder how common this actually is. Not many people analyze the gRNA sequence in their down stream analysis either

[Taylor Hudson @Trae_1992]

@honglue1 I really enjoyed this paper! It mirrot many trends I've observed in off-target screening throughout the years. It would be interesting to translate these findings into a more applied framework of off-target detection

[U.S. FDA @US_FDA]

LIVE NOW: FDA's Cell and Gene Therapy Roundtable
Captions available here: https://t.co/QyRYlaur9t
https://t.co/9KAwikJEiv

[Taylor Hudson @Trae_1992]

@UCBerkeley It's such an honor to lead de-risking efforts at IGI for this case!

[The New York Times @nytimes]

Breaking News: A baby with a rare disorder made medical history by receiving the first custom gene-editing treatment. The technique used has the potential to help people with thousands of other uncommon genetic diseases. https://t.co/6RB5ttiKmX

[David R. Liu @davidrliu]

In a medical milestone, a customized base editor was developed, characterized in human and mouse cells, tested in mice, studied for safety in non-human primates, cleared by @US_FDA for clinical trial use, manufactured as a complex with an LNP, and dosed into a baby with a severe, rapidly progressing genetic disease... all in an astounding 7 months. Best of all, the infant patient shows apparent benefit. Congratulations to @kiranmusunuru, Rebecca Ahrens-Nicklas, and other team members for this heroic and inspiring effort, which has implications for the hundreds of millions of patients that suffer from thousands of genetic diseases.

https://t.co/wsgvvRYPVM

[NEJM @NEJM]

Presented at #ASGCT2025:

A lipid nanoparticle–delivered base-editing therapy was custom designed for an infant with a ureacycle disorder. The affected infant was treated at approximately 7 and 8 months of age.

Read the Brief Report: https://t.co/B695kT9DRn

Editorial: Progress in the Development of N-of-1 Therapy https://t.co/PzvWMNfyVP

Science behind the Study: Personalized Gene Editing to Treat an Inborn Error of Metabolism https://t.co/mJSKHr5HIR

@ASGCTherapy

[Taylor Hudson @Trae_1992]

@honglue1 @doudna_lab @Noor_AlSayyad @kevin_wasko Amazing! I wonder if this explains why we often see that high performing gRNAs also have high specifity. Possibly cutting efficiency is partially due to less time binding to off-target sites ?

[Taylor Hudson @Trae_1992]

@dr_alphalyrae So refreshing to hear!! I chose academia in the Bay Area to escape that mentality, but I was naive. Even academia is how "loud can we speak" instead of the integrity of our words. Biotechs are frequently funders instead of NIH and scientist using grandiloquent rhetoric.

[Vermont Public @vermontpublic]

Green Up Day is around the corner. We learn about grassroots efforts across the state to remove trash from our communities.

https://t.co/r4B5laKjwD

[The PhD Place @ThePhDPlace]

Thank you to the people that aggressively nod during presentations.

[Taylor Hudson @Trae_1992]

@JohnDoench @CellGenomics Cloning a suite for Cas constructs in several days! …. But grad students around the world will spend less time doing tedious/time consuming tasks? How awful would that be